Ivonescimab expands China label as Summit awaits US test

China's NMPA approved ivonescimab plus chemotherapy as a first-line treatment for advanced squamous non-small cell lung cancer, expanding its indications to three lung cancer settings in China. Summit Therapeutics anticipates FDA review in the US, where ivonescimab's global Phase III trial compares it directly with pembrolizumab, underscoring a potential commercial breakthrough for the PD-1×VEGF bispecific antibody approach.

This Wire brief sits within Fusion42's coverage of Biotech.